MAY 0 2 2007 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Francois Shutze et al.) Group Art Unit: 1617
Application No.: 10/532,041) Examiner: CARLIC K HUYNH
Filing Date: June 23, 2006	Confirmation No.: 5818
Title: PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND AN ANTI-INFLAMMATORY AGENT)))

COPENDING INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

form F	Enclosed is a Copending Information Disclosure Statement (IDS) and accompanying PTO-1449 for the above-identified patent application.
\boxtimes	No additional fee for submission of an IDS is required.
	The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
	A statement under 37 C.F.R. § 1.97(e) is also enclosed.
	A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
	Charge to Deposit Account No. 02-4800 for the fee due.
	A check in the amount of is enclosed for the fee due.
	Charge to credit card for the fee due. Form PTO-2038 is attached
\boxtimes	The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.
	Respectfully submitted,
	BUCHANAN INGERSOLL & ROONEY PC

Melissa M. Haywooth Registration No. 45774

By:

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620

Attorney Docket No. <u>1032013-000121</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Francois Shutze et al.

Application No.: 10/532,041

Filing Date: June 23, 2006

Title: PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND AN ANTI-INFLAMMATORY AGENT

Croup Art Unit: 1617

Examiner: CARLIC K HUYNH

Confirmation No.: 5818

COPENDING INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

form	Enclosed is a Copending PTO-1449 for the above-ide			ent (IDS) and accompanying
\boxtimes	No additional fee for subr	nission o	f an IDS is required.	•
	The fee of \$ 180 as set fo	orth in 37	C.F.R. § 1.17(p) is als	so enclosed.
	A statement under 37 C.F	F.R. § 1.9	7(e) is also enclosed.	
	A statement under 37 C.F. § 1.17(p) are a			180 as set forth in
	Charge	to Depo	sit Account No. 02-48	00 for the fee due.
	A check in the amount of		is enclosed t	or the fee due.
	Charge	to credit	card for the fee due.	Form PTO-2038 is attached.
\boxtimes	The Director is hereby au 37 C.F.R. §§ 1.16, 1.17 a any overpayment, to Depduplicate.	nd 1.21 t	hat may be required b	y this paper, and to credit
		Resp	ectfully submitted,	
		Buch	HANAN INGERSOLL & RO	DONEY PC
Date	1 May 2007	Ву:	Melissa M. Haywoodh Registration No. 457	

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent A	Application of)	
Francois Shu	tze et al.)	Group Art Unit: 1617
Application 1	No.: 10/532,041)	Examiner: CARLIC K HUYNH
Filed: June	23, 2006)	Confirmation No.: 5818
CON	RMACEUTICAL COMPOSITION MBINING TENATOPRAZOLE AND ANTI-INFLAMMATORY AGENT)))))	

COPENDING INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56 and the Examiner's request in the Office Action dated 11 September 2006 for copending application U.S. Serial No. 10/532,114, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Copending Information Disclosure Statement
Application No. 10/532,041
Attorney Docket No. 1032013-000121
Page 2

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: Man 2007

Bv:

Melissa M. Hayworth

Registration No. 45774

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620

O le - 414 4 -		1449/PTO &	4.4.4.0.D./D.T.C
Substitute	TOT TOTAL	1 1449/210 6	14490/210

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known
Application Number	10/532,041
Filing Date	June 23, 2006
First Named Inventor	Francois Shutze et al.
Examiner Name	CARLIC K HUYNH
Attorney Docket No.	1032013-000121

MAY 0 2 2007

Sheet 1 of

	U.S. PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)		
	7,034,038		Cohen et al.	04-25-2006		
	2006-0194832	A1	Cohen et al.	08-31-2006		
	2007-0066659	A1	Schutze et al.	03-22-2007		
	2006-0241136	A1	Schutze et al.	10-26-2006		
		l				

	FOREIGN PATENT DOCUMENTS										
					STATUS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
		 									

	NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	U.S. Serial No. 10/561,844 "Monohydrated Sodium Salt of S-Tenatoprazole and the Use Thereof in Therapy", filed December 22, 2005, attorney docket no. 1032013-000133.				

Examiner Signature	Date Considered	•		
-----------------------	--------------------	---	--	--